Drug intelligence / Profile preview

GM-CSF + carboplatin + mitomycin C + vinorelbine

Development stage: Unknown
Lead developer: Johnson Matthey
Modality: Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination chemotherapy regimen consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF), carboplatin, mitomycin C, and vinorelbine. This regimen was developed for the treatment of advanced non-small cell lung carcinoma (NSCLC). The combination was chosen based on the known activity of these agents in NSCLC and their potential drug synergism without overlapping non-hematologic toxicities. GM-CSF is included specifically to prevent or counteract neutropenia, which is the anticipated dose-limiting toxicity.

Targets

TUBB (Tubulin (alpha and beta subunits))CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)DNA

Beyond the preview

Go deeper on GM-CSF + carboplatin + mitomycin C + vinorelbine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GM-CSF + carboplatin + mitomycin C + vinorelbine.

Explore the full profile